Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atomoxetine
- Development stage
- Approved
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI) used primarily for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children over six years old and adults. It works by selectively inhibiting the presynaptic norepinephrine transporter in the brain to increase levels of norepinephrine and dopamine in the prefrontal cortex—regions involved in attention and impulse control. Unlike stimulant medications for ADHD such as methylphenidate or amphetamines, atomoxetine is not a controlled substance and does not have significant abuse potential. Atomoxetine was originally developed by Eli Lilly and Company as an antidepressant but was repurposed after showing efficacy for ADHD. It is typically used as part of a comprehensive treatment program that may include psychological or educational interventions[1][2][3][4][5][6][7].
- Brand names
- StratteraAxetraAxeptaAtteraTomoxetinAttentinMylanAuroxetynStramoxAtentahAttexSetinoxAtominex
- Other names
- atomoxetine hydrochloride
02
Targets
KCNJ3 (GIRK1)KOR (Kappa opioid receptor)NET (Norepinephrine Transporter)NMDAR (Glutamate receptor ionotropic, NMDA)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on atomoxetine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atomoxetine.